Get The App!
Loading the player...
How Often Do You Monitor CBC after a Patient Reaches His/Her Stable Ruxolitinib Dose?
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
Dr. Ruben Mesa, Mayo Clinic, answers the following question: How often do you monitor CBC after a patient reaches his/her stable ruxolitinib dose?
In Patients with PV, What Clinical Triggers Would Lead You to Perform a Bone Marrow Biopsy?
What Factors Do You Use to Determine If an MF Patient Is, or Is Not, Benefitting from Long-Term Ruxo...
How Long Do MF Patients Typically Stay on Ruxolitinib Therapy? What Are the Main Reasons for Discont...
Do Post-PV MF and Primary MF have Different Clinical Courses and/or Prognosis?
What Steps Do You Take for Differential Assessment/Treatment of Debilitating Fatigue in Patients wit...
Does Development of HU-Refractory PV Increase a Patient’s Risk for Thrombosis/Cardiovascular Events?...
Would Pregnancy Change the Management of Young Woman with Low-Risk PV? Do You Alter Antithrombotic T...
Should Patients Continue to Receive Anti-Platelet Therapy/Anticoagulation after Progression to Post-...
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go